Goddard J, Johnston NR, Cumming AD, Webb DJ. Fractional urinary excretion of endothelin-1 is reduced by acute ETB receptor blockade. Am J Physiol Renal Physiol 293: F1433-F1438, 2007. First published September 12, 2007; doi:10.1152/ajprenal.00101.2007.-Evidence suggests that urinary excretion of endothelin-1 (ET-1) reflects renal ET-1 production and is independent of systemic ET-1 activity. The influence of ET receptors on urinary ET-1 excretion has not been studied in humans, yet peritubular ETB receptors are abundant within the kidney. We have studied the effects of acute ETA and ETB receptor blockade with BQ-123 and BQ-788, respectively, on urinary ET-1 excretion in a randomized, placebo-controlled, doubleblind study in 16 subjects with a wide range of GFRs (15-152 ml/min). Plasma ET-1 concentrations (pET-1) and urinary ET-1 excretion rate (uET-1) at baseline correlated inversely with GFR (R 2 ϭ 0.18 and 0.36, respectively, P Ͻ 0.01). However, changes in pET-1 after ET receptor antagonism were not related to changes in uET-1 (R 2 ϭ 0.007, P ϭ 0.18). pET-1 increased only after BQ-788, alone or in combination with BQ-123, consistent with ETB receptormediated clearance of ET-1 from the circulation. uET-1 was reduced only after BQ-788 alone [Ϫ4.7 pg/min (SD 5.5), P Ͻ 0.01]. Because BQ-788 also reduced GFR, fractional excretion of ET-1 (FeET-1) was calculated. FeET-1 fell after BQ-788 alone [Ϫ41% (SD 26%), P Ͻ 0.01] or in combination with BQ-123 [Ϫ40% (SD 29%), P Ͻ 0.01]. FeET-1 was not altered by placebo or BQ-123 alone. In conclusion, urinary ET-1 excretion does not appear to relate to the pool of plasma ET-1. Because of the short duration of this study, it is unlikely that ET receptor blockade had significant effects on renal ET-1 production. Therefore, the reduction in FeET-1 after ETB blockade appears to indicate that renal excretion of ET-1 is at least partly facilitated by ETB receptor activation.kidney; human ENDOTHELIN-1 (ET-1) is largely removed from the circulation by receptor (ETB)-mediated mechanisms, primarily in the pulmonary circulation (2, 4, 5). However, the kidneys remove ϳ10% of ET-1 from the circulation in humans (5). As a small peptide, ET-1 in plasma should be filtered at the glomerulus, and, because clearance from plasma is dependent on filtration, is receptor independent. After filtration, in common with most polypeptides, ET-1 is likely to be hydrolyzed at the brush border and the constituent peptides and amino acids reabsorbed in the tubules and metabolized. In rats, although up to 15% of plasma ET-1 is extracted across the renal bed (2), Ͻ1% of injected radiolabeled ET-1 is recovered in the urine (1a). In these isotope studies, the failure of plasma ET-1 to appear in the urine implies that neither glomerular filtration nor tubular secretion of plasma ET-1 accounts for urinary ET-1, which is therefore assumed to be primarily of renal origin. In support of this, cortical interstitial concentrations of ET-1 have been shown to correlate with urinary ET-1 excretion (23).In chronic kidney dis...